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with stable/ refractory disease fared similarly with regard to OS
and PFS. Day 100, 2-year TRM and OS/PFS data appear very
encouraging in these very high-risk, extensively pretreated pa-
tients. Response status at transplant seems to affect outcome, and
PD remains a major obstacle.
63
VACCINATION WITH DENDRITIC CELL MYELOMA FUSIONS ALONE OR
IN CONJUNCTION WITH STEM CELL TRANSPLANTATION FOR PATIENTS
WITH MULTIPLE MYELOMA
Avigan, D.1, Rosenblatt, J.1, Vasir, B.2, Wu, Z.2, Bisonette, A.2,
Macnamarra, C.1, Uhl, L.1, Lenahan, C.1, Miller, K.1, Joyce, R.1,
Levine, J.1, Proper, J.1, Forino, P.1, Donbagoda, D.1, Munshi, N.2,
Kufe, D.2 1Beth Israel Deaconess Medical Center, Boston, MA; 2Dana
Farber Cancer Institute, Boston, MA.
We have demonstrated that patient derived myeloma cells fused
with autologous dendritic cells (DCs) potently stimulate anti-tu-
mor immunity in vitro. We are conducting phase I clinical trials in
which patients with myeloma undergo serial vaccination with DC/
myeloma fusions alone or in conjunction with stem cell transplan-
tation. To date, 18 patients have been enrolled (11- vaccine alone,
7 vaccine following autologous stem cell transplant). To generate
mature DCs, adherent mononuclear cells were isolated from a
leukapharesis collection and cultured with GM-CSF, IL-4, and
TNF . The mean yield and viability of the DC preparations was
1.5  108 cells and 88%, respectively. Patient derived myeloma
cells were isolated from bone marrow aspirates and were quantiﬁed
by the expression of CD38 and/or CD138. The mean yield and
viability of the myeloma cell collections was 7.3  107 cells and
89%, respectively. Fusion cells were generated by coculture of
DCs with myeloma cells in the presence of 50% polyethylene
glycol. The mean fusion efﬁciency was 40% as determined by the
percentage of cells that co-expressed unique DC and myeloma
antigens. In contrast to myeloma cells, the DC and fusion cell
preparations prominently stimulated allogeneic T cell proliferation
in vitro. To date, 13 patients have completed vaccination at a dose
of 1-5  106 fusion cells. GM-CSF (100 g) was administered
subcutaneously on the day of vaccination and for 3 days thereafter.
Adverse events judged to be potentially vaccine related have in-
cluded vaccine injection site reactions, edema, rash, fever, chills,
fatigue, muscle aches, pruritis, and diarrhea. One patient with a
history of prior deep venous thrombosis (DVT) developed a DVT
and pulmonary embolus of uncertain relation to the vaccine. To
date, a majority of evaluable patients demonstrated evidence of
vaccine induced anti-myeloma immunity as demonstrated by at
least 2 fold increase in IFN expression by CD4 and/or CD8 T
cells in response to ex vivo exposure to autologous tumor lysate. Of
patients undergoing vaccine therapy alone, 5 patients demon-
strated stabilization of the myeloma paraprotein for 2-6 months
following initiation of vaccination. Of 3 patients completing post-
transplant vaccination, 2 patients demonstrated resolution of the
persisting myeloma protein post-transplant and 1 patient demon-
strated a transient increase followed by a decline in paraprotein
levels post-transplant.
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INTERLEUKIN-6 AND HEMATOPOIETIC SOLUBLE FACTORS CONFERS
RESISTANCE TO TRAIL MEDIATED APOPTOSIS
Perez, L.E.1, Parquet, N.1, Shain, K.2, Molisano, M.1,
Nimmanapalli, R.2, Alsina, M.1, Anasetti, C.1, Dalton, W.2 1BMT
Division, H. Lee Mofﬁtt Cancer Center, Tampa, FL; 2Hematology
Division, H. Lee Mofﬁt Cancer Center, Tampa, FL.
The bone marrow microenvironment provides tumor protection
from chemotherapy and Fas-death receptor mediated apoptosis
through a process known as environmental mediated death resis-
tance (EM-DR). TRAIL, a member of the TNF superfamily, has
anti-tumor activity sparing normal cells and mediates allogeneic
graft-versus-tumor responses. We hypothesized that the tumor
microenvironment inﬂuences TRAIL mediated killing conferring
an immune resistance mechanism contributing to cancer progres-
sion in allogeneic transplantation. Experiments in a transwell
(TW) assay with RPMI-8226-Myeloma cells in the upper well and
HS5- hematopoietic stromal cells in the bottom well (TWHS5)
revealed that HS5 cells blocked recombinant human(rh-) TRAIL-
induced apoptosis through soluble factors in a dose and time-
dependent manner. RPMI-8226 treated in TWHS5 exhibited
attenuated pro-caspase-8, pro-caspase-3, PARP, and BID cleavage,
with diminished mitochondrial membrane potential changes, with-
out alterations on TRAIL receptors. Western blotting of RPMI-
8226 cells showed that Fas-associated death domain like IL-1
converting enzyme-like inhibitory protein (FLIP), a regulatory
factor that competes with caspase-8 inhibiting apoptosis, is in-
creased in TWHS5 treated cells. Subcellular fractionation of
RPMI-8226 cells showed that FLIP is maintained in or associated
with organelle membranes and is released to the cytosol when
exposed to soluble factor (TWHS5) suggesting that that soluble
factor signaling may inﬂuence FLIP localization and availability.
FLIP reduction by FLIP-RNA interference or with Bortezomib,
NF-KB inhibitor that reduces FLIP levels, increases TRAIL apo-
ptosis sensitivity of RPMI-8226 cells treated in TWHS5. To
explore whether IL-6, important myeloma survival factor, is in-
volved in TRAIL-EMDR, RPMI-8226 treated with HS27a stroma
that lack IL-6 secretion elicit a diminished apoptosis resistance
compared to HS-5. In addition, RPMI-8226 treated in TWHS5
with an anti-human IL-6 neutralizing antibody partially overcome
the TRAIL apoptosis resistance. Furthermore, rh-IL-6 confers
resistance to TRAIL mediated apoptosis in a dose-dependent man-
ner associated with FLIP increase. Our results suggest that IL-6
and other soluble factors produced by marrow stromal cells pro-
mote myeloma cell survival by upregulating FLIP, thereby miti-
gating the inﬂuence of the microenvironment on TRAIL-induced
apoptosis. The immune cytotoxic effect of TRAIL may be en-
hanced by FLIP inhibitors.
PEDIATRIC DISORDERS
65
THE USE OF CYCLOPHOSPHAMIDE (CY), FLUDARABINE AND ATG AS A
PREPARATIVE REGIMEN FOR UNRELATED CORD BLOOD TRANSPLAN-
TATION (UCBT) IN FANCONI ANEMIA: A SINGLE CENTER EXPERIENCE
IN 27 PATIENTS
Bonﬁm, C.1, Bitencourt, M.1, Setubal, D.1, Funke, V.1, Ruiz, J.1,
Oliveira, M.1, Coutinho, E.1, deMedeiros, C.1, Zanis-Neto, J.1,
Pasquini, R.1 1Stem Cell Transplantation Unit UFPR, Curitiba,
Parana, Brazil.
Stem cell transplantation from HLA identical siblings can cure
over 80% of FA pts when they develop bone marrow failure
syndromes. Unrelated CB is a good option for pts lacking a
matched bone marrow unrelated donor, but the transplant pro-
cedure is complicated by a high incidence of graft failure and
delayed immune recovery. From 01/03 to 05/06 we transplanted
27pts with FA in aplastic phase. Gender: 8M/19F. Age:4-
19years (M:8y). Disease duration: 19-78months (M:36m). Pre-
vious transfusions : 1-85UI (M:12) .HLA Compatibility: 6/6:
3pts ; 5/6:9pts and 4/6:15pts. Preparatory regimen: CY60mg/
kg Fludarabine125mg/m2  Rabbit ATG 4mg/kg. GVHD
Prophylaxis: Cyclosporine (Csa)  steroids:22pts or Csa 
MTX: 5pts.TNC infused before thawing: 2,3 – 19,2 10^7/kg
(M: 5,4). One pt received a double UCBT with a TNC of 5,2
10^7. Results: 11pts are alive between 135-1301 days after
UCBT(M: 806d). 21pts survived  28 d and were evaluable for
engraftment. 13pts (48%) had a complete hematological recov-
ery and the median time to reach ANC500/ul was 23 d(12-
35d) and platelets  20.000/ul was 27 d(15-50d). Primary graft
failure occurred in 6pts and 2pts had only a neutrophil engraft-
ment. Most pts (6/8pts) without hematological recovery re-
ceived a 4/6 CB. No pt survived a 2nd or 3rd UCBT. Post-
transplant complications: Mucositis grade III-IV: 10pts (grade
IV: 1pt). Hemorrhagic cystitis: 5pts.Hemolytic uremic syn-
drome:1pt. Moderate/severe hypertension: 70% of pts. Neuro-
Oral Presentations26
